EBS:NYSE
Emergent Biosolutions Inc
$6.09
arrow_downward
-5.80%(-0.38) 1D
Sep 3, 2:59:43 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for EBS...
Open
$6.56
High
$6.60
Low
$5.97
Mkt. cap
312.25M
Avg. vol.
1.28M
Volume
558.29K
52-wk high
$14.06
52-wk low
$4.36
EPS
-$3.51
Beta
2.34
Shares outstanding
51.27M
No. of employees
900
Open
$6.56
High
$6.60
Low
$5.97
Mkt. cap
312.25M
Avg. vol.
1.28M
Volume
558.29K
52-wk high
$14.06
52-wk low
$4.36
EPS
-$3.51
Beta
2.34
Shares outstanding
51.27M
No. of employees
900
News stories
From web sources and news partners
Investing.com
·
6 hours ago
Emergent BioSolutions repurchases $75 million in senior notes
Stock Titan
·
7 hours ago
A $68 million cash outlay retires $75 million in Emergent bond debt
Investing.com
·
2 days ago
Emergent BioSolutions receives $24M anthrax vaccine contract
Profile
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid.
During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded. Wikipedia
About Emergent Biosolutions Inc
CEORobert G. Kramer Sr. | Joseph C. Papa
Employees900
FoundedSep 5, 1998
HeadquartersRockville, Maryland, United States
SectorBiotechnology
Websiteemergentbiosolutions.com